glp 1 mash approval Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists Semaglutide targets MASH molecular pathways

Vitamin D Receptor Is Overexpressed in the Duodenum of Patients With Irritable Bowel Syndrome

The body can produce levocarnitine from the amino acids lysine and methionine, although its also available through dietary sources such as meat, fish, and dairy products

34,35 However, the controversy surrounding the possible benefits of GIPR agonism stems from two main observations: its impaired insulinotropic effects, 36,37 and the prevention of weight gain by suppression of endogenous GIP-induced adipogenesis, 38,39 However, these seemingly discouraging observations have been questioned by the finding of the central anorexic effects of GIP, 4042 and benefits of the GLP-1R/GIPR dual agonist LY3298176 (tirzepatide) in diabetic and overweight individuals

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimers disease

pylori -induced rise in plasma leptin (49) could contribute to the loss of appetite in infected patients